Product Details
Synonym
MSLN, Mesothelin, MPF
Source
PE-Labeled Human Mesothelin (296-580) Protein, His Tag (MSN-HP2H5) is produced via site-specific conjugation of PE to Human Mesothelin (296-580), His Tag under optimal conditions with a proprietary technology. Human Mesothelin (296-580), His Tag is expressed in HEK293 cells containing AA Glu 296 - Gly 580 (Accession # AAH09272).
Predicted N-terminus: Glu 296
Request for sequenceMolecular Characterization
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 35.87 kDa.
Conjugate
PE
Excitation Wavelength: 488 nm / 561 nm
Emission Wavelength: 575 nm
Application
Evaluation of anti-MSLN CAR expression by flow cytometry. Please note that this product is NOT compatible to streptavidin detection system.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, 0.5% BSA, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
Bioactivity-FACS

1e6 of the anti-MSLN CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human Mesothelin (296-580) Protein, His Tag (Cat. No. MSN-HP2H5) and negative control protein respectively, PE signal was used to evaluate the binding activity (QC tested).
Protocol
Customer Reviews Writing Reviews

Background
Recent Advances
- English Name:
Mesothelin
- Category:
- Approved Drugs:
0 Details
- Drugs in Clinical Trials:
41 Details
- Highest Development Stage:
Phase 2 Clinical
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
















